Galvita AG

📍 Basel, Switzerland🗓 Founded 2020👥 10 employees💰 Last funded May 2024
Biotechnology Research🌐 galvita.com
Website LinkedIn
Welcome to a new class of drug delivery systems for ODTs: Galvitas TIP-Technology! Galvita’s revolutionary, patented, and repeatedly clinically tested technology enables the production of micro capsules (Templated Inverted Particles / TIP) that can be loaded with many different active ingredients and easily compressed to tablets with excellent mechanical strength. The unique properties of TIP-based tablets offer many benefits over other oral dosage forms, such as ultra-rapid disintegration (5-10 sec), fast onset of action (reduced first-pass effect), water-free ingestion (no swallowing), smaller tablet sizes, taste masking and a neutral product composition (100% pure calcium phosphate TIP, compendial and inorganic material). Galvita offers licensing of the patented technology, value adding services in formulation development such as feasibility/early formulation, R&D and scale-up support, as well as support in setting up and conducting clinical testing and studies .
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in Galvita AG?
Galvita AG has 1 investors on record on gritt.io, 1 mid-stage.
When did Galvita AG last raise funding?
The most recent investment in Galvita AG recorded on gritt.io was in May 2024.
When was Galvita AG founded?
Galvita AG was founded in 2020.
What industry is Galvita AG in?
Galvita AG operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Galvita AG based?
Galvita AG is headquartered in Basel, Switzerland.